<?xml version="1.0" encoding="UTF-8"?>
<p>Tumor necrosis factor-α levels are moderately increased in patients with SARS, but higher levels have been observed in patients with COVID-19 and correlate with disease severity [
 <xref ref-type="bibr" rid="CR35">35</xref>]. Tumor necrosis factor inhibitors might be effective in reducing SARS-CoV2 infection and the associated organ damage, by decreasing TNF-α-converting enzyme-dependent shedding of the ACE2 ectodomain, which is crucial for the penetration of SARS-CoV2 into the cell [
 <xref ref-type="bibr" rid="CR36">36</xref>]. A study evaluating adalimumab in COVID-19 infection has recently been registered in the Chinese Clinical Trial Registry (ChiCTR2000030089).
</p>
